首页> 外文期刊>British journal of ophthalmology >Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis
【24h】

Earlier use of systemic immunosuppression is associated with fewer ophthalmic surgeries in paediatric non-infectious uveitis

机译:早期使用全身免疫抑制与儿科非传染性葡萄膜炎的眼科手术较少

获取原文
获取原文并翻译 | 示例
       

摘要

Background/aims There is a paucity of large trials investigating the effect of management strategies for paediatric non-infectious uveitis on complications requiring surgery. The purpose of our study is to investigate whether earlier initiation of systemic immunosuppression in paediatric non-infectious uveitis is associated with fewer ophthalmic surgeries. Methods A retrospective review was conducted on 48 children with non-infectious uveitis assessed in 1998-2013. Patients were divided into uveitis diagnosed before December 2008 (group 1) and after January 2009 (group 2). Duration from uveitis onset to methotrexate initiation (U-MTX) and biological addition (U-Biologic) were reviewed. Follow-up visits with topical corticosteroids >3 times daily and active uveitis (>= 1+ cells) during 3.5 years were documented. The main outcome measure was the need for >= 1 ophthalmic surgery at 3.5 years. Results In group 1, 69.5% of patients required >= 1 ophthalmic surgery at 3.5 years versus 26.9% in group 2 (p=0.005). U-MTX was 28.9 +/- 11.8 weeks and 14.2 +/- 10.0 weeks for groups 1 and 2 (p=0.028). U-Biologic was 134.6 +/- 46.0 weeks and 82.3 +/- 43.3 weeks for groups 1 and 2 (p=0.0016). Corticosteroid use >3 times daily was 85.9 +/- 52.7 weeks and 14.6 +/- 11.1 weeks for groups 1 and 2. Multivariate regression showed methotrexate initiation within 6 months of uveitis onset lowered the likelihood of needing ophthalmic surgery at 3.5 years (OR=6.2, 95% CI 1.2 to 33.4; p=0.033). Univariate regression demonstrated biological addition within 18 months of uveitis onset reduced the likelihood of requiring ophthalmic surgery (OR 12.57, 95% CI 1.28 to 123.48; p=0.030). Conclusion Earlier control of uveitis by addition of immunosuppressive therapy reduced the need for ophthalmic surgery.
机译:背景/宗旨是缺乏大型试验,调查对小儿非传染性葡萄膜炎的管理策略对需要手术的并发症的影响。我们研究的目的是探讨早期对儿科无传染性葡萄膜炎的系统性免疫抑制是否与较少的眼科手术相关联。方法采用1998 - 2013年评估的48例非传染性葡萄膜炎的48例患儿进行回顾性评论。患者分为2008年12月之前诊断的葡萄膜炎(第1组)和2009年1月(第2组)。从葡萄膜发作到甲氨蝶呤开始(U-MTX)和生物添加(U-Biologic)的持续时间进行了审查。记录了3次与局部皮质类固醇的随访3次,每日3次,有效葡萄膜炎(> = 1+细胞)记录。主要结果措施是需要> = 1眼科手术3.5岁。结果1,69.5%的患者需要> = 1次眼科手术3.5岁,2组中26.9%(p = 0.005)。 U-MTX为28.9 +/- 11.8周,组1和2的14.2 +/- 10.0周(P = 0.028)。 u-Biologic为134.6 +/- 46.0周和组1和2的82.3 +/- 43.3周(p = 0.0016)。皮质类固醇使用>每日3次为85.9 +/- 52.7周和14.6 +/-11.1周,组1和2.多元回归显示甲氨蝶呤在葡萄膜炎的6个月内发育出来降低了3.5岁时需要眼科手术的可能性(或= 6.2,95%CI 1.2至33.4; p = 0.033)。单变量回归在葡萄膜炎发病18个月内表现出生物加法,降低了需要眼科手术的可能性(或12.57,95%CI 1.28至123.48; P = 0.030)。结论通过添加免疫抑制治疗早期对葡萄膜炎的控制减少了对眼科手术的需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号